USFDA inspects Torrent's Levittown facility

News: Torrent's manufacturing facility at Levittown, US was inspected by USFDA between December 6 and 15, 2021 with no Form 483 being issued.

View: Levittown facility was part of Torrent Pharma's acquisition of Bio-Pharm in 2018 and received a warning letter from USFDA in October, 2019. Levittown facility has manufacturing capabilities for oral solutions, suspensions and suppositories along with  controlled substances. US remains muted for Torrent while contributing 16% of topline in FY21 and regulatory clearances will help Torrent Pharma in diversifying its pipeline with complex products through new approvals

Impact: Positive